NRXP Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
NRX Pharmaceuticals Inc (NRXP) is not a strong buy for a beginner, long-term investor at this time. Despite some positive developments in financial performance and analyst optimism for the future, the lack of significant short-term catalysts, neutral trading sentiment, and bearish technical indicators suggest waiting for a clearer entry point.
The MACD is positive and expanding, indicating potential upward momentum. However, the RSI is neutral at 60.244, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). Key resistance levels are at 1.95 and 2.018, with support at 1.728 and 1.66. Overall, the technical indicators suggest a mixed to bearish trend.
Analyst optimism with a price target raised to $48, citing major opportunities for NRX-100 and NRX-101 with FDA action dates in
Improved financial performance in Q3 2025, with a significant YoY increase in net income and EPS.
Bearish technical indicators with moving averages signaling a downward trend.
Neutral trading sentiment from hedge funds and insiders.
No recent news or significant short-term catalysts.
In Q3 2025, revenue remained flat at $242,000 YoY. However, net income improved significantly to -$5.89M, up 262.91% YoY. EPS also improved to -0.26, up 73.33% YoY. Gross margin remained steady at 49.17%. While the financials show improvement, the company is still operating at a loss.
Ascendiant maintains a Buy rating and raised the price target to $48 from $47, citing major opportunities for NRX-100 and NRX-101. However, these catalysts are expected to materialize in 2026, making them less relevant for immediate investment decisions.
